Curia (RNA/Advanced) vs ST Pharm: CDMO Comparison
Side-by-side comparison of Curia (RNA/Advanced) and ST Pharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Curia (RNA/Advanced) carries a cleaner inspection mix — no OAI classifications versus 1 for ST Pharm.
- Curia (RNA/Advanced) has materially broader EMA GMP coverage (16 active certificates vs 4) — stronger EU footprint.
On a 13-modality CDMO landscape, both Curia (RNA/Advanced) and ST Pharm qualify as mRNA/LNP manufacturers; Curia (RNA/Advanced) carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both Curia (RNA/Advanced) and ST Pharm qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: Curia (RNA/Advanced) vs ST Pharm
Which has the stronger FDA inspection record, Curia (RNA/Advanced) or ST Pharm?
Curia (RNA/Advanced) has 2 FDA inspections on record (NAI 1 / VAI 1 / OAI 0) and 0 warning letters. ST Pharm has 2 FDA inspections on record (NAI 0 / VAI 1 / OAI 1) and 0 warning letters.
How do Curia (RNA/Advanced) and ST Pharm compare on European GMP coverage?
Curia (RNA/Advanced) holds 16 active EMA GMP certificates and 0 MHRA / UK certificates. ST Pharm holds 4 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for mRNA/LNP manufacturing — Curia (RNA/Advanced) or ST Pharm?
Both Curia (RNA/Advanced) and ST Pharm are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Curia (RNA/Advanced) carries a Signal Score of 79/100 and ST Pharm carries 73/100 — a small lead for Curia (RNA/Advanced). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →